Neuralstem Announces Topline Results Of Phase II ALS Trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Boston Scientific discloses cybersecurity incident causing global disruption
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
ALS Data Shows Neuralstem (CUR) Approach is 'Risky' - Maxim Group
March 12, 2015 1:13 PM EDTMaxim Group analyst Jason Kolbert weighed in on Neuralstem (NYSE: CUR) after the company reported ALS phase II data this morning.
Kolbert commented, "The press release is worded in a complex way and on the surface appears positive; "7/15 patients may have responded"; however after carefully evaluating the complete press release, it leaves us concerned on several fronts. Multiple injections into the spine is risky and based on our interpretation of the data maybe accelerating the disease. Why so negative? Both... More
Neuralstem (CUR) Announces NSI-566 Phase 2 Met Primary Safety Endpoints
March 12, 2015 6:53 AM EDTNeuralstem (NYSE: CUR) announced top line data from the Phase II trial of NSI-566 spinal cord-derived neural stem cells under development for the treatment of amyotrophic lateral sclerosis (ALS). The study met primary safety endpoints. The maximum tolerated dose of 16 million transplanted cells and the surgery was well tolerated.
Secondary efficacy endpoints at nine months post-surgery indicate a 47% response rate to the stem cell treatment, as measured by either near-zero slope of decline or positive slope of ALSFRS score in seven out of 15 patients and by either a near-zero decline, or positive... More
